Novartis has filed suit against AstraZeneca’s rare disease unit, claiming that certain marketing materials for Alexion’s Ultomiris create an inaccurate impression of Novartis’ rival drug Fabhalta.

The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON, Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...

(Alliance News) - AstraZeneca PLC on Thursday said its investigational complement C5 inhibitor gefurulimab showed statistically significant results in treating adults with a form of generalised ...

Among people with sickle cell disease—an inherited blood disorder—acute chest syndrome (ACS) is the leading cause of death. The condition is the result of red blood cells becoming stiff, sticky, and ...

Sickle cell disease can lead to a severe complication known as acute chest syndrome (ACS), but the underlying mechanisms are not well understood. A new study by Mass General Brigham investigators ...

AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing partner JCR Pharmaceuticals to develop genomic medicines. Under the deal, ...

The complement system is a key component of innate and adaptive immunity and therefore acts as a vital defense against invading pathogens. Deficiencies in the complement system are associated with ...

When AstraZeneca’s Alexion picked up rare disease specialist Syntimmune in 2018 for $400 million, the latter’s FcRn inhibitor dubbed SYNT001 was the crown jewel of the deal. After Alexion scrapped its ...